June Helen Myklebust is an Associate Professor at the Institute for Cancer Research, Faculty of Medicine, University of Oslo. Her research focuses on B-cell lymphoma, cancer immunology, and tumor microenvironment with particular emphasis on B-cell receptor signaling and germinal center biology. She maintains a strong research presence at Oslo University Hospital Radiumhospitalet where she conducts laboratory research and collaborates with clinical teams. Dr. Myklebust's primary research interests include: Mechanisms of B-cell receptor signaling in lymphoma Tumor microenvironment and immune interactions in B-cell malignancies Development of novel immunotherapies including CAR T-cell approaches Genomic and molecular characterization of lymphoma subtypes Understanding mechanisms of transformation in indolent lymphomas Analysis of her recent publications reveals a strong focus on translational cancer research with emphasis on B-cell lymphoma biology. Her work spans from basic molecular mechanisms of B-cell signaling to clinical applications of immunotherapy. A significant portion of her research investigates how tumor cells interact with the immune system, particularly focusing on T cell exhaustion and regulatory mechanisms within the tumor microenvironment. Her laboratory employs advanced techniques including single-cell profiling, mass cytometry, and genomic analysis to understand lymphoma heterogeneity and evolution. Dr. Myklebust maintains an active research program with numerous collaborations both nationally and internationally. Her work has appeared in high-impact journals including Blood, Cancer Cell, and Nature family journals, demonstrating the significance of her contributions to the field of lymphoma research. She is actively involved in mentoring researchers and collaborating with clinical teams to translate basic research findings into potential therapeutic approaches for lymphoma patients. Her laboratory work focuses on understanding the molecular mechanisms driving lymphomagenesis and identifying novel therapeutic targets.
جستوجوی استاد و پژوهشگر
استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشیتان را پیدا کنید و با او ارتباط بگیرید.
نمایش ۱۶-۳۰ از ۱۷۲ استاد راهنما
اطلاعات این پروفایلها از صفحات عمومی دانشگاهها جمعآوری شده و ممکن است بهروز نباشد.
Linda N. Daoمشاهده پروفایل
استاد بالینی
Linda N. Dao, M.D. is a Clinical Professor in the Department of Laboratory Medicine and Pathology at Mayo Clinic College of Medicine and Science. She specializes in Hematopathology and Surgical Pathology with primary clinical focus at the Rochester, Minnesota campus. Her educational background includes: MD from Texas Tech University School of Medicine (2005) Bachelor of Arts from The University of Texas at Austin (2001) Residency in Anatomic and Clinical Pathology at Mayo Clinic (2009) Fellowships in Hematopathology (2011) and Surgical Pathology (2010) Dr. Dao's research centers on amyloidosis characterization using advanced proteomic techniques, with significant contributions to mass spectrometry-based amyloid typing. Her work spans multi-organ amyloid deposition including salivary glands, spleen, gastrointestinal tract, and bone marrow. Current investigations focus on developing minimally invasive lymphoma detection methods through blood plasma biomarkers. Analysis of her 15 most recent publications reveals a dominant focus on amyloidosis subtyping through proteomics (68% of articles), with emerging work in molecular diagnostics for hematologic malignancies. Key methodological trends include large-scale validation studies (>16,000 samples) and clinicopathologic correlation frameworks. Professional recognition includes: American Board of Pathology certification in Hematopathology (2022) American Board of Pathology certification in Anatomic & Clinical Pathology (2009) Dr. Dao actively contributes to academic leadership through committee service including Pathology Residency Clinical Competency Committee (2015-present), Pathology Residency Recruitment Committee (2011-2016), and Professional Development Sub-Committee (2013-2017). She maintains active membership in the Society for Hematopathology, American Society for Clinical Pathology, and College of American Pathologists.
- Biomedicine
- Virology
- Oncology
- +۵ مورد دیگر
Gabriella Lillsunde-Larsson is a Senior Lecturer and Associate Professor at the Örebro University School of Health Sciences , with a 30% appointment at the Department of Laboratory Medicine, Örebro University Hospital. Her work bridges biomedical laboratory science and clinical oncology , focusing on HPV-induced cancers and translational research. PhD in Biomedicine (2015) - Thesis: Characterization of HPV-induced vaginal and vulvar carcinoma Current research projects: HPV gene variation and protein expression as prognostic markers Molecular triage for cervical screening Prognostic biomarkers in prostate cancer Research Focus: Gabriella investigates biological and prognostic factors in HPV-induced genital cancers, prostate cancer, and endocannabinoid signaling. Her work includes cost-effectiveness analysis of self-sampling methods and international collaborations on cervical screening policies. Publications: Recent work explores molecular triage in cervical screening, HPV genotyping in HIV-endemic regions, and protein expression markers in vaginal carcinoma. Her studies (2022-2025) emphasize translational applications of HPV research and laboratory science innovations. Academic Leadership: Program Manager for the Master's Program in Methods in Medical Diagnostics Vice Chair of the Institute of Biomedical Laboratory Science (IBL) President of the International Federation of Biomedical Laboratory Science (IFBLS) since 2024 Örebro University representative in the Regional Cancer Center (RCC) Central Sweden International Engagement: Active in WHO collaborations through IFBLS, scientific committee member for global HPV congresses, and contributor to professional education standards across Nordic countries.
Asolina Braunمشاهده پروفایل
پژوهشگر ارشد
- Skin Immunology
- Autoimmunity
- Psoriasis
- +۷ مورد دیگر
Dr. Asolina Braun is a Senior Research Fellow at the Department of Biochemistry & Molecular Biology, Monash University. She actively supervises PhD students and contributes to research in Skin Immunology Psoriasis Pathogenesis Immunopeptidomics Tissue-Resident Memory T Cells . Education : Biology, Hannover Medical School Doctoral Degree in Immunology (Hannover Medical School, Germany, 2011–2014) Postdoctoral Fellowship with Francis Carbone and Thomas Gebhardt (Germany, 2014–2018) Research Focus : Her work explores HLA-Cw6-dependent antigen presentation and TRM cell survival factors in psoriasis, aiming to develop tolerization strategies for autoinflammatory skin diseases. She also pioneered tactile science communication methods for psoriasis outreach. Key Projects : Leading Psoriasis Antigen Triggers (2023–2025) Investigating Influenza Immune Cross-Protection (2024–2027) Validating HLA-Cw6 Antigen Presentation (2020–2022) Awards & Roles : DFG Fellowship Treasurer, Australian and New Zealand Society for Immunology (2018–2022) Executive Committee Member Collaborations span institutions in Australia, Germany, and Denmark, with expertise in flow cytometry , mass spectrometry , and MHC-peptide interactions .
Dr. Min Shi, M.D., Ph.D., is a distinguished hematopathologist at Mayo Clinic in Rochester, Minnesota, specializing in hematologic disorders. She serves as a faculty member in the Department of Laboratory Medicine and Pathology with significant contributions to clinical practice, research, and education in hematopathology. Dr. Shi's educational background includes: 2014: Fellow in Hematopathology, Brigham & Women's Hospital 2013: Resident in Anatomic and Clinical Pathology, University of Massachusetts Medical School 2009: Post Doctoral Associate in Immunology, University of Massachusetts Medical School 2008: Ph.D. in Immunology, University of Massachusetts Medical School 2001: Resident in OB-GYN, Peking Union Medical College Hospital 1996: M.D., Beijing Medical University Dr. Shi's research focuses on hematopathology with particular expertise in flow cytometry applications for hematologic malignancies. Her work spans bone marrow pathology, lymph node pathology, minimal residual disease detection, and diagnostic innovations in hematologic disorders. She has pioneered approaches for T-cell receptor analysis using flow cytometry and has contributed significantly to understanding large granular lymphocytic leukemia diagnostics. Her extensive publication record demonstrates leadership in advancing diagnostic methodologies for hematologic malignancies, particularly in flow cytometry applications. Her recent work emphasizes artificial intelligence integration in diagnostic workflows, validation of minimal residual disease testing, and characterization of complex genetic abnormalities in leukemias and lymphomas. Dr. Shi has received numerous scientific awards including: 2020 Editors Best Original Paper published in Clinical Cytometry 2019 and 2016 Mayo Quality Fellows Gold projects 2009 AAI Trainee Abstract Award Multiple Lin Qiaozhi Awards for Outstanding Clinical Research As an educator, Dr. Shi provides mentorship to residents, fellows, and clinical laboratory staff. She serves in leadership roles including as Chair of the International Clinical Cytometry Society Education Committee and as Co-Director of the Cell Kinetics Laboratory. Her professional memberships span numerous hematology and pathology organizations including the Society for Hematopathology, American Society of Hematology, and College of American Pathologists. Dr. Shi leads the Cell Kinetics Laboratory at Mayo Clinic, focusing on flow cytometry diagnostics for hematologic malignancies. Her team develops and validates novel flow cytometry approaches for minimal residual disease detection and immunophenotypic characterization of lymphoid and myeloid disorders.
Ying-Hsia Chuمشاهده پروفایل
استادیار
Ying-Hsia Chu serves as Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota, where she leads research at the intersection of molecular pathology and head/neck-thyroid oncology. Her work bridges diagnostic histopathology with genomic characterization to address clinically challenging carcinomas. Research Focus: Dr. Chu specializes in gene fusion discovery (e.g., STAT6, RAF1, NOTCH1), non-coding RNA mechanisms in cancer progression, and development of RNA sequencing diagnostics for sinonasal tract and thyroid malignancies. Her fingerprint analysis confirms dominant expertise in neoplasm (100%), thyroid carcinoma (84%), and phosphotransferase pathways (69%), with significant contributions to understanding long non-coding RNAs in anaplastic carcinomas. Publication Trends: Analysis of her 35 publications (2013-2025) reveals accelerating output since 2020, with 2022-2025 works emphasizing actionable genomic alterations (e.g., FGFR rearrangements, MET skipping) and expanded histological spectra in HPV-associated carcinomas. This trajectory demonstrates increasing influence in precision oncology diagnostics, particularly through multi-institutional collaborations. Collaborative Impact: Dr. Chu's nationwide studies on oral cavity cancer (e.g., 2023 neck dissection analysis with 18 Scopus citations) demonstrate translational impact on surgical guidelines. Her work engages international networks including Taiwanese institutions and major US cancer centers, though specific laboratory structures remain unreported in available materials.
- Nuclear Medicine
- Prostate Cancer Imaging
- Radiomics
- +۳ مورد دیگر
Giorgio Brembilla is a Researcher in Medicine at the Vita-Salute San Raffaele University, specializing in medical imaging and oncology. His research focuses on advanced imaging techniques such as PET/MRI and PSMA-based radiotracers for prostate cancer diagnosis and management. He leads studies on lymph node detection, radiomics signatures, and predictive modeling for surgical outcomes. His work integrates clinical, imaging, and genomic data to improve diagnostic accuracy and treatment strategies. Affiliations: Vita-Salute San Raffaele University, Department of Medicine (implied). Teaching: Courses include 'Imaging in Urology' and 'Imaging of the Musculoskeletal System.' Key research interests include the development of hybrid imaging workflows, AI-driven segmentation of tumor lesions, and risk stratification models for kidney and prostate cancers. His recent studies address external validation challenges in radiomics and the impact of imaging quality on prostate cancer detection. Publications highlight contributions to PSMA PET-based radiomics, preoperative risk calculators, and the diagnostic accuracy of hybrid imaging modalities. Collaborations focus on translational research bridging imaging and clinical oncology.
Dr. Justin Bishop is the Jane B. and Edwin P. Jenevein, M.D. Chair in Pathology and Professor and Chief of Anatomic Pathology at the University of Texas Southwestern Medical Center. He specializes in surgical pathology of head and neck diseases and endocrine pathology, with a focus on tumor classification and HPV-related cancers. His research includes the molecular characterization of salivary gland and sinonasal tumors, such as DEK-AFF2 fusion-associated carcinomas and SMARCB1-deficient carcinomas. Dr. Bishop has authored over 250 journal articles, 35 book chapters, and 9 books, including the WHO Classification of Head and Neck Tumors . He serves as editor-in-chief of Seminars in Diagnostic Pathology and associate editor for Modern Pathology and JAMA Otolaryngology-Head and Neck Surgery . His work bridges clinical diagnosis and molecular pathology, emphasizing genetic and immunohistochemical markers for tumor classification. Recent studies highlight novel fusions (e.g., STRN-ALK, MEF2C-SS18) and their diagnostic implications. Dr. Bishop’s contributions to tumor classification and editorial leadership have solidified his role as a leading authority in head and neck pathology.
Jovan Brankov is a Professor of Electrical and Computer Engineering and Biomedical Engineering at the Illinois Institute of Technology (IIT), within the Armour College of Engineering. He joined IIT in 2002 as a researcher, became Research Assistant Professor in 2004, and was promoted to Assistant Professor in 2008. His research focuses on medical imaging, image sequence processing, pattern recognition, and data mining, with emphasis on biomedical applications such as tumor detection, motion tracking, and tomographic reconstruction methods. Education: Ph.D. in Electrical Engineering from IIT (2002), M.Sc. from IIT (1999), and Dipl. Ing. from the University of Belgrade (1996). Research interests include medical image quality assessment, multiple-image radiography, 4D/5D tomographic reconstruction, and the ADEPT cancer imager. He leads the Advanced X-ray Imaging Laboratory (AXIL) at IIT, which develops phase-sensitive x-ray imaging technologies. Key awards include the IOP Select Award (2006), AIP Editor's Pick (2015), and Nayar Prize phases I (2015) and II (2016). He serves as an associate editor for IEEE Transactions on Medical Imaging, Medical Physics, and SPIE's Journal of Medical Imaging. His work spans over 150 publications, including peer-reviewed articles and a book chapter. Ongoing projects involve deep learning applications in SPECT imaging, fluorescence-guided surgery, and paired-agent imaging for cancer detection.
Dr. Giovanni Battista Di Pierro is a Researcher at the Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome. His work focuses on urological oncology, robotic/laparoscopic surgery, and molecular diagnostics. MD, Summa Cum Laude (2006) - Sapienza University of Rome Specialization in Urology, Summa Cum Laude (2012) - Sapienza University PhD candidate in 'Advanced Technology in Surgery' (ongoing) Key research areas span: Prostate cancer recurrence and biomarker development (DDR genes, PLR/NLR ratios) Bladder cancer diagnostics (CEUS, urinary biomarkers) Robotic/laparoscopic surgery comparisons and complication analysis Regenerative medicine applications for urinary incontinence Recent publications (2022-2024) emphasize meta-analytical approaches, imaging innovations, and precision oncology. His work appears in top journals like European Urology, Cancers, and Journal of Clinical Medicine. Best Original Paper of European Urology 2011 EAU Clinical Fellowship (2010) Active in clinical research with multidisciplinary teams focused on DDR gene analysis in urological malignancies.
Ifeyinwa E. Obiorah, M.D., Ph.D. serves as an Associate Professor of Pathology at the University of Virginia School of Medicine, specializing in Hematopathology within the Department of Pathology. Her clinical practice focuses on hematopathology diagnostics with particular expertise in lymphoma subtyping. Her research centers on molecular characterization of T-cell lymphomas, especially cutaneous variants, with significant contributions to understanding megakaryocyte abnormalities in myelofibrosis, RUNX1 germline mutations, and diagnostic flow cytometry innovations. Recent work explores lymphoma transformation mechanisms, CNS involvement patterns, and technological advances in urine analyzers. Her publication pattern shows consistent high-impact contributions across hematology, oncology, and laboratory medicine journals. Dr. Obiorah maintains active research collaborations evidenced by multi-institutional publications. Her work bridges diagnostic pathology with translational research, particularly in lymphoma classification systems and germline predisposition to hematologic malignancies. The PubMed record confirms her as a consistently productive researcher with 46 indexed publications spanning 2008-2025. She has contributed extensively to diagnostic methodology refinement, particularly regarding: Molecular classification systems for lymphomas Germline mutation implications in myeloid neoplasms Flow cytometry adaptations for novel therapies Cutaneous lymphoma diagnostic criteria Her educational background includes medical training at Nnamdi Azikiwe University (Nigeria), Anatomic/Clinical Pathology residency at Georgetown University, and Hematopathology fellowship at the National Institutes of Health - reflecting a strong foundation in both clinical practice and research methodology.
- Breast Cancer
- Oncology
- Metastasis Prediction
- +۴ مورد دیگر
Lisa Ryden is a Professor and Senior Consultant Surgeon at Lund University's Department of Surgery. She serves as Principal Investigator at the Lund University Cancer Centre (LUCC) and manages multiple breast cancer research projects including the Liquid Biopsy and Tumor Progression in Breast Cancer initiative and Breast Cancer Surgery projects. Dr. Ryden's research focuses on improving prediction models for regional and distant metastatic spread in breast cancer to enable personalized treatment selection. Her work integrates patient, clinical, and tumor-related data to achieve high accuracy in prediction. She characterizes archival tumor tissue from primary tumors and metastasis on protein and genomic levels, linking these characteristics to clinical outcomes. A key aspect of her research involves developing models to identify node-negative breast cancer patients who might avoid axillary surgery. Her multidisciplinary research group includes clinical PhD students, clinical researchers, biostatisticians, molecular biologists, and technical personnel. Her work contributes to UN Sustainable Development Goals related to health and well-being. Honorary Skou Professor (2019) Reutersköldska Priset i Kirurgi (Reutersköld award in Surgery) (2019) Nordiska Medicinpriset (2016) Dr. Ryden actively supervises research students and leads multiple significant projects including 'Optimizing and individualizing adjuvant radiotherapy in breast cancer' and 'The T-REX trial.' Her research has been supported by Cancerfonden, Familjen Erling-Perssons Stiftelse, Bröstcancerförbundet, and Sjöbergstiftelsen. She is actively involved in organizing conferences and workshops through LUCC, demonstrating strong leadership in the breast cancer research community with activities extending into 2025.
Johan Staafمشاهده پروفایل
دانشیار
- Cancer Research
- Bioinformatics
- Molecular Oncology
- +۴ مورد دیگر
Johan Staaf is an Associate Professor and Senior Lecturer at Lund University, affiliated with the Lund University Cancer Centre (LUCC) and the Division of Translational Cancer Research . As a principal investigator and project manager, he leads research initiatives in lung cancer and triple-negative breast cancer (TNBC) , focusing on molecular characterization, biomarker discovery, and translation to clinical diagnostics. Expertise: Genomics, Epigenetics, Bioinformatics, Precision Cancer Medicine Projects: 8 active and 6 finished grants, including genomic markers for chemotherapy response in TNBC and DNA repair deficiency analysis in ER+ breast cancer. His work emphasizes multi-omics integration and machine-learning to redefine molecular taxonomies, identify prognostic biomarkers , and develop blood-based assays for early cancer detection and relapse monitoring. He supervises PhD students and collaborates internationally. Scientific Awards: Senior Investigator Award - Swedish Cancer Society (2019) Key Contributions: Landmark studies on BRCA1 mutations vs. hypermethylation in TNBC, circulating tumor DNA applications, and immune landscape characterization via image analysis. He also contributes to UN Sustainable Development Goals in cancer research and global health equity.
Geoffrey P. Luke is Associate Professor of Engineering at Dartmouth's Thayer School of Engineering, directing the Functional and Molecular Imaging Lab. His research develops nanoparticle-enhanced ultrasound and photoacoustic imaging for cancer diagnostics and therapy. Current projects include multiplex imaging of tumor biomarkers using phase-change nanodroplets and NIH-funded oral cancer detection systems. Publications focus on advanced contrast agents (gold nanorods, perfluorocarbon nanodroplets) and wavelength-optimized spectroscopic imaging for applications in sentinel lymph node mapping and image-guided photothermal therapy. Recent work emphasizes clinical translation of hybrid imaging modalities.
Laurence Chapuyمشاهده پروفایل
استاد مدعو
Laurence Chapuy, MD, PhD is an Associate Investigator at the Research Institute of the McGill University Health Centre (RI-MUHC) and an Adjunct Professor in the Department of Pediatrics, Faculty of Medicine and Health Sciences at McGill University. He is affiliated with the Infectious Diseases and Immunity in Global Health Program and the Centre for Translational Biology at RI-MUHC. Dr. Chapuy's research focuses on immunological mechanisms underlying inflammatory bowel diseases (IBD). His work specifically examines the role of innate immune cells, particularly mononuclear phagocytes, in the inflammatory and fibrotic processes of patients with Crohn's disease and ulcerative colitis. His laboratory employs advanced techniques including single-cell RNA sequencing, transcriptomic analysis, and high-dimensional phenotypic mapping to characterize immune cell populations in intestinal mucosa and mesenteric lymph nodes. Analysis of Dr. Chapuy's recent publications reveals a consistent focus on cellular immunology in IBD, with particular emphasis on mononuclear phagocytes, CD14+ subsets, and Th17/Th1 responses. His work demonstrates significant differences in immune cell profiles between Crohn's disease and ulcerative colitis, providing insights into disease mechanisms and potential therapeutic targets. His research spans both adult and pediatric IBD populations, with recent work examining very early onset and early onset IBD in pediatric cohorts. As an Associate Investigator at RI-MUHC, Dr. Chapuy leads a research program investigating mucosal immunology in inflammatory bowel diseases. His work bridges basic immunology with clinical applications, aiming to translate findings into improved understanding and management of IBD. His research is conducted in collaboration with multiple investigators at McGill University and the McGill University Health Centre.